Astheneia Bio has agreed to terms and is negotiating a licensing agreement for a first line cancer therapy to begin phase 1 this year. The phase 1 is an open-label, dose-escalation and expansion, first-in human trial to evaluate safety, tolerability, PK, pharmacodynamics, and preliminary efficacy in a multitude of solid and liquid tumors.
Astheneia Bio is negotiating a licensing agreement for a first in class and first line HPV+ and associated tumors immunotherapy with an estimated IND filing mid-2026.
The website contains forward looking statements about the scientific expectations of the data gathered to date. We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events or otherwise.
Copyright © 2024 Astheneia Bio - All Rights Reserved.